371 related articles for article (PubMed ID: 35100336)
1. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis.
Albert MH; Slatter MA; Gennery AR; Güngör T; Bakunina K; Markovitch B; Hazelaar S; Sirait T; Courteille V; Aiuti A; Aleinikova OV; Balashov D; Bernardo ME; Bodova I; Bruno B; Cavazzana M; Chiesa R; Fischer A; Hauck F; Ifversen M; Kałwak K; Klein C; Kulagin A; Kupesiz A; Kuskonmaz B; Lindemans CA; Locatelli F; Lum SH; Maschan A; Meisel R; Moshous D; Porta F; Sauer MG; Sedlacek P; Schulz A; Suarez F; Vallée TC; Winiarski JH; Zecca M; Neven B; Veys P; Lankester AC
Blood; 2022 Mar; 139(13):2066-2079. PubMed ID: 35100336
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
[TBL] [Abstract][Full Text] [Related]
3. Busulfan-fludarabine- or treosulfan-fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties.
Cseh A; Galimard JE; de la Fuente J; Isgro A; Zecca M; Garwer B; Biffi A; Aljurf M; Sundin M; Belendez C; Locatelli F; Balduzzi A; Lawson S; Sengeloev H; Ifversen M; Saccardi R; Wynn R; Lankester AC; Corbacioglu S; Peters C
Br J Haematol; 2024 Jan; 204(1):e1-e5. PubMed ID: 37795523
[TBL] [Abstract][Full Text] [Related]
4. CD3
Ramanathan S; Lum SH; Nademi Z; Carruthers K; Watson H; Flood T; Owens S; Williams E; Hambleton S; Gennery AR; Slatter M
Transplant Cell Ther; 2023 Aug; 29(8):513.e1-513.e9. PubMed ID: 37279857
[TBL] [Abstract][Full Text] [Related]
5. Successful Reduced Intensity Conditioning Alternate Donor Stem Cell Transplant for Wiskott-Aldrich Syndrome.
Thakkar D; Katewa S; Rastogi N; Kohli S; Nivargi S; Yadav SP
J Pediatr Hematol Oncol; 2017 Nov; 39(8):e493-e496. PubMed ID: 28859032
[TBL] [Abstract][Full Text] [Related]
6. A Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRαβ
Balashov D; Laberko A; Shcherbina A; Trakhtman P; Abramov D; Gutovskaya E; Kozlovskaya S; Shelikhova L; Novichkova G; Maschan M; Rumiantsev A; Maschan A
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1432-1440. PubMed ID: 29550630
[TBL] [Abstract][Full Text] [Related]
7. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
[TBL] [Abstract][Full Text] [Related]
8. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.
Morillo-Gutierrez B; Beier R; Rao K; Burroughs L; Schulz A; Ewins AM; Gibson B; Sedlacek P; Krol L; Strahm B; Zaidman I; Kalwak K; Talano JA; Woolfrey A; Fraser C; Meyts I; Müller I; Wachowiak J; Bernardo ME; Veys P; Sykora KW; Gennery AR; Slatter M
Blood; 2016 Jul; 128(3):440-8. PubMed ID: 27216217
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Saraceni F; Labopin M; Brecht A; Kröger N; Eder M; Tischer J; Labussière-Wallet H; Einsele H; Beelen D; Bunjes D; Niederwieser D; Bochtler T; Savani BN; Mohty M; Nagler A
J Hematol Oncol; 2019 Apr; 12(1):44. PubMed ID: 31023346
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
11. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation.
Lucchini G; Labopin M; Beohou E; Dalissier A; Dalle JH; Cornish J; Zecca M; Samarasinghe S; Gibson B; Locatelli F; Bertrand Y; Abdel-Rahman F; Socie G; Sundin M; Lankester A; Sedlacek P; Hamladji RM; Heilmann C; Afanasyev B; Hough R; Peters C; Bader P; Veys P
Biol Blood Marrow Transplant; 2017 Mar; 23(3):467-474. PubMed ID: 27916512
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen.
Parta M; Shah NN; Baird K; Rafei H; Calvo KR; Hughes T; Cole K; Kenyon M; Schuver BB; Cuellar-Rodriguez J; Zerbe CS; Holland SM; Hickstein DD
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1250-1259. PubMed ID: 29412158
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
[TBL] [Abstract][Full Text] [Related]
14. Matched Family versus Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Thalassemia Major: Experience from a Tertiary Referral Center in South India.
Swaminathan VV; Uppuluri R; Patel S; Ravichandran N; Ramanan KM; Vaidhyanathan L; Ramakrishnan B; Jayakumar I; Raj R
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1326-1331. PubMed ID: 32200123
[TBL] [Abstract][Full Text] [Related]
15. Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia.
Hong KT; Park HJ; Kim BK; An HY; Choi JY; Kang HJ
Transplant Cell Ther; 2022 Apr; 28(4):195.e1-195.e7. PubMed ID: 35021131
[TBL] [Abstract][Full Text] [Related]
16. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor.
Devillier R; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Harbi S; Granata A; D'Incan E; Coso D; Chabannon C; Picard C; Etienne A; Calmels B; Schiano JM; Lemarie C; Stoppa AM; Bouabdallah R; Vey N; Blaise D
Am J Hematol; 2014 Jan; 89(1):83-7. PubMed ID: 24108528
[TBL] [Abstract][Full Text] [Related]
17. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
[TBL] [Abstract][Full Text] [Related]
18. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
19. Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.
Slatter MA; Rao K; Abd Hamid IJ; Nademi Z; Chiesa R; Elfeky R; Pearce MS; Amrolia P; Worth A; Flood T; Abinun M; Hambleton S; Qasim W; Gaspar HB; Cant AJ; Gennery AR; Veys P
Biol Blood Marrow Transplant; 2018 Mar; 24(3):529-536. PubMed ID: 29155317
[TBL] [Abstract][Full Text] [Related]
20. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
